A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of WRAIR Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in Puerto Rico
Phase of Trial: Phase I
Latest Information Update: 25 May 2017
At a glance
- Drugs TDENV PIV (Primary) ; Aluminium hydroxide; AS01E; AS03B
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- 22 May 2017 Status changed from active, no longer recruiting to completed.
- 02 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 25 Feb 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.